Subcutaneous trastuzumab‑pertuzumab before surgery for Algerian women with locally advanced HER2‑positive breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, observational real‑world study conducted at three oncology centers in Algeria that will follow about 70 adult women with non‑metastatic HER2‑positive breast cancer. Participants receive the fixed‑dose subcutaneous combination of trastuzumab and pertuzumab (Phesgo) together with standard chemotherapy for roughly 18 weeks, followed by surgical removal of the tumor. The main outcome is pathological complete response (pCR) in the breast and axillary lymph nodes; secondary outcomes include rate of breast conservation, safety and tolerability, quality of life, patient satisfaction, and biomarkers or factors that predict response. Results aim to describe how well the subcutaneous regimen works and how feasible and acceptable it is in routine oncology practice in Algeria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female participants aged 19 years or older.
* Histologically confirmed HER2-positive breast cancer (by immunohistochemistry and/or in situ hybridization), non-metastatic.
* Candidate for neoadjuvant therapy according to local clinical practice.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* Left ventricular ejection fraction (LVEF) ≥ 50%.
* Signed written informed consent.

Exclusion Criteria:

* Evidence of distant metastases.
* Prior anti-HER2 therapy.
* Known contraindications to trastuzumab or pertuzumab.
* Pregnancy or breastfeeding.
* Disease progression during neoadjuvant treatment (if already started).
* Refusal of surgery.
* Withdrawal of consent.

Where it's running

• Medical oncology department - Anti Cancer Center of Blida
  Blida, Algeria Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Paclitaxel micelles with HER2-targeted therapy vs standard taxane-based therapy as first-line treatment for advanced HER2-positive breast cancer

  This study tests whether paclitaxel polymer micelles plus trastuzumab, pertuzumab, and ad Adelumab can better treat advanced HER2-positive breast cancer compared with the usual taxane-based therapy plus trastuzumab and pertuzumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07581795

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

• KN026 plus HB1801 with chemotherapy as adjuvant treatment after surgery for resectable HER2-positive breast cancer

  This study will test whether giving KN026 and HB1801 with chemotherapy after surgery helps people with resectable HER2-positive breast cancer more than the usual trastuzumab plus pertuzumab with chemotherapy.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT07441460

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.